U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT06951997) titled 'QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer' on April 23.
Brief Summary: This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma.
Study Start Date: May 15
Study Type: INTERVENTIONAL
Condition:
Metastatic Pancreatic Cancer
Intervention:
DRUG: QL1706
5mg/kg, q3w
DRUG: Chidamide
20mg, biw, q3w
DRUG: Gemcitabine
1000mg/m2 Q3W
DRUG: Nab-paclitaxel
125mg/m2 Q3W
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Tianjin Medical Uni...